-
Innovation Ranking
NewInnovation Ranking – HLB Co Ltd
HLB Co Ltd (HLB) is an early-stage drug development company. Its product is a cytotoxic antineoplastic drug. The company carries out research and development, clinic, pharmaceutical distribution, healthcare venture capital, and medical device production. HLB also manufactures lifeboats and electrical instruments. The company produces lifeboats for marine plants, drillships and cruise vessels. Its lifeboats include conventional type, free fall and rescue boats. The company also carries out the pipe business and biotechnology business. HLB is headquartered in Ulsan, South Korea.
-
Company Insights
Innovation and Patenting activity of HLB Co Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of HLB Co Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Company Insights
Innovation and Patenting activity of HLB Therapeutics Co Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of HLB Therapeutics Co Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Company Insights
Innovation and Patenting activity of HLB Life Science Co Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of HLB Life Science Co Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rotigotine in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rotigotine in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rotigotine in Parkinson's Disease Drug Details: Rotigotine (MFP-013) is under development for...
-
Product Insights
Adenoid Cystic Carcinoma (ACC) – Drugs In Development, 2023
Global Markets Direct’s, ‘Adenoid Cystic Carcinoma (ACC) - Drugs In Development, 2023’, provides an overview of the Adenoid Cystic Carcinoma (ACC) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Adenoid Cystic Carcinoma (ACC), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Adenocarcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Adenocarcinoma - Drugs In Development, 2023’, provides an overview of the Adenocarcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Adenocarcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Sepsis – Drugs In Development, 2023
Global Markets Direct’s, ‘Sepsis - Drugs In Development, 2023’, provides an overview of the Sepsis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Sepsis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Sector Analysis
EGFR Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033
EGFR Tests Market Report Overview The EGFR tests market size was $17.4 million in 2023 and it will grow at a CAGR of less than 1% during 2023-2033. Epidermal growth factor receptor gene (EGFR) tests are carried out to detect mutations within this receptor gene in non-small cell lung cancer tumor cells. The outcome of may determine if EGFR-targeted tyrosine kinase inhibitors such as gefitinib and erlotinib may be beneficial for treating non-small cell lung cancer (NSCLC). EGFR Tests Market...
-
Product Insights
Keratoconjunctivitis Sicca (Dry Eye) – Drugs In Development, 2023
Global Markets Direct’s, ‘Keratoconjunctivitis Sicca (Dry Eye) - Drugs In Development, 2023’, provides an overview of the Keratoconjunctivitis Sicca (Dry Eye) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Keratoconjunctivitis Sicca (Dry Eye), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...